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Prostaglandin E2 (PGE2)-mediated suppression of macrophage interleukln-1a43 and
tumor necrosis factor-a synthesis was examined at the cellular and molecular levels.
Treatment of lipopolysaccharide (LPS)-stimulated adjuvant-elicited murine macrophages
with 5 x 107M PGE2 caused a 70% reduction in cell-associated TNF but had no
suppressive effect on cell-associated lnterleukin-1 (IL-i) activity. Consistent with this
result, Northern blot and nuclear transcription analyses demonstrated suppression of
TNF mRNA but PGE2 had no effect on IL-i a and IL-i  mRNA accumulation, as compared
to LPS controls. immunoperoxidase staining for cell-associated TNFa, IL-i a, and IL-i l
demonstrated that PGE2 suppressed TNF, but not IL-la or -t3 expression, supporting the
bioassay data. These results imply that PGE2-mediated regulation of lL-ia,( and TNFa is
quite distinct. Synthesis of TNF appears to be regulated at least at the level of
transcription, whereas that for IL-la and - is regulated post-transcriptionally.
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INTRODUCTION
Interleukin- 1 (IL-i) and tumor necrosis factor (TNF)
are polypeptide products of macrophages that mediate a
wide array of biological activities, involving a variety of
target cell populations. Although these cytokines are
biochemically and immunologically distinct, they share a
number of common physiological functions, including
the induction of fever, activation of neutrophils, inhibi-
tion of lipoprotein lipase, induction of procoagulant
activity on endothelial cells, induction of surface anti-
gens on endothelial cells, and activation of fibroblasts
[1-5].
Macrophages are the major sources of IL- 1a, IL-i 3,
and TNFa [6,7]. Interestingly, stimulation of macro-
phages with a polyclonal stimulant such as lipopolysac-
charide (LPS) will result in the liberation of not only the
above cytokines, but also products of arachidonic acid
metabolism, including prostaglandin E2 (POE2). Our
laboratory and others have examined the potential role of
POE2 in the modulation of macrophage cytokine produc-
tion. We and others have demonstrated that POE2 causes
a dose-dependent suppression of IL-i and TNF release
from LPS-stimulated macrophages [8-il]. These studies
implicated a regulatory function of endogenously pro-
duced PGE2 in the release of IL-l and TNF from
stimulated macrophages. In addition, the evidence that
IL-i or TNF alone will stimulate the release of PGE2
from monocytes and macrophages [9, ii, 12] is consistent
with an autoregulatory loop in which release of these
monokines from stimulated macrophages will serve to
induce an endogenous inhibitor of further cytokine re-
lease. The focus of the present study was to elucidate the
mechanisms of POE2-mediated suppression of IL-ia,
IL- 1 , and TNFa release from stimulated munne macro-
phages by examining its effect on mRNA synthesis and
the cellular accumulation of these activities.
MATERIALS AND METHODS
Animals and Macrophage Cultures
Adult female CBAIJ H2k mice (Jackson Labs, Bar
Harbor, ME) were maintained under pathogen-free con-
ditions and given food and water ad libitum. Macro-
phages were elicited by the intraperitoneal injection of
0.5 ml of complete Freund’s adjuvant (CFA) (Sigma
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Chemical Co., St. Louis, MO) mixed 1:1 with sterile
saline. Peritoneal cells were harvested 2 wk later by
aseptic peritoneal lavage with RPMI i640 containing
antibiotics (Gibco, Detroit, MI). Macrophages were
aiiowed to adhere in 35-mm culture dishes at 37#{176}C,5%
C02, 95% air for 2 h. Nonadherent cells were then
removed by washing with warm RPMI, and the resulting
monoiayers were overlayed with media containing i
p..g/m1 LPS (Escherichia coli, 01 ii :B4, Sigma Chemical
Co., St. Louis, MO) or media alone. Previous studies in
our laboratory have demonstrated adherent cells prepared
in this way to be greater than 95% macrophages and
greater than 80% Ia-positive. In prostaglandin experi-
ments, monolayers were treated with prostaglandin E2
(POE2) (kindly provided by Upjohn Co., Kalamazoo,
MI), concomitant with LPS or control media. For
monokine bioactivity determinations, the adherent cells
were washed thrice with warm media, scraped into i ml
of medium, and repeatedly frozen and thawed for assess-
ment of celi-associated IL-i and/or TNF.
Messenger RNA Analysis
At designated intervals after stimulation, total RNA
was isolated from macrophage monolayers using a mod-
ification of the method of Chirgwin and Jonas [13,14].
RNA samples (10 pg/sample) were examined by North-
ern blot analysis, using formaldehyde 1% agarose gels.
The separated RNA samples were transblotted to nitro-
ceiiuiose, baked, prehybridized and hybridized using
32P-iabeied probes. The following oligonucleotides and
cDNAs were utilized in this study: a) murine TNFa
(30-mer) 5 ‘-OTCCCCCTFCTCCAGCTGGAAOAC-
TCCTCC-3’[15]; b) munne IL-i a (26-mer) 5 ‘-OTOAA-
GGTCFCACTOAAACTCAGCCO-3’ [i6]; c) murine
IL-i f3_(30-mer) 5 ‘-TFCTATCTFOTFOAAOACAAA-
CCOC’iTiiC-3’ [i7]; d) murine actin (42-mer) 5’-
GGCT0000TGTFGAAGGTCTCAAACATGATCTG-
GGTCATCTT-3’ [18]; e) full-length cDNA probe for
TNFa, (kindly provided by Cetus Corp., Emeryville,
CA), [19]; and 0 cDNA for murine IL-la, (kindly
provided by Dr. Peter Lomedico, Hoffman LaRoche,
Nutley, NJ). Hybridized blots were washed and autora-
diographed with intensifying screens.
Monoklne Assays
Interleukin- 1 levels were measured using the standard
thymocyte coproliferation assay as modified from the
procedure of Mizel et al. [20]. One unit of interleukin- i
activity was defined as the amount of material causing
half-maximal stimulation in the co-proliferation assay.
The LM fibroblast cell line was used to measure levels
of TNF according to a modification of the procedure of
Ruff and Gifford [2i]. Serial dilutions of test samples
were added to 96-well microtiter plates (Costar, Cam-
bridge, MA) containing LM cells (5 x l0 cells/well)
plus actinomycin D (final concentration 1 rig/well).
Recombinant human TNF (Cetus Corp., Emeryville,
CA) was used as a positive control in this assay. The
cells were incubated at 37#{176}Cfor i8 h, supernatants were
discarded, and the remaining viable adherent cells
stained. The absorbance of each well was read at 540 nm
with a MicroELISA autoreader. Units of TNF were
defined as the reciprocal of the dilution at which 50%
cytotoxicity occurs.
Antibodies and Immunohistochemistry
Antimurine TNFa was produced by immunization of
rabbits with recombinant murine TNFa administered in
multiple intradermal sites with complete Freund’s adju-
vant. Anti-IL-ia and -13 were prepared by similar im-
munization of a goat and a rabbit, respectively, with
recombinant murine IL-i a or IL-i 13 (Pfizer Central
Research, Dept. Molecular Genetics, Oroton, CT).
These antisera reacted with appropriate proteins in West-
ern blot analysis. In competitive inhibition experiments,
to demonstrate antibody specificity, immunostaining for
murine TNFa, IL-ia, and 13 showed nearly 100%
inhibition by exogenous addition of respective recombi-
nant cytokines with virtually no cross-reactivity. Immu-
nolocalization studies were performed as follows.
Macrophage monolayers were fixed for 5 mm in 4%
paraformaldehyde in PBS and rinsed twice with PBS.
Prior to staining they were fixed for 3 mm in absolute
methanol. The slides were rinsed again with PBS and
then treated with a 3% hydrogen peroxide solution to
inactivate any remaining peroxidase activity. The slides
were next blocked with a i :50 dilution of normal goat or
rabbit serum, then decanted and exposed to dilutions of
anti-TNFa (i : i ,000), anti-IL-ia (1:2,000), anti-IL- 113
(i:i,000) or a similar dilution of control serum. After 10
mm incubation at 37#{176}C,the slides were rinsed, overlaid
with biotinylated goat antirabbit IgO (i :200) or rabbit
antigoat IgG (1:200) (Vector Laboratories, Burlingame,
CA) and incubated, followed by three additional rinses
with PBS. The slides were next treated with peroxidase-
labeled streptavidin (Sigma), incubated again, rinsed
thrice, then overlaid with substrate chromogen (3-amino
9-ethyl carbazole) for 5 mm at 37#{176}Cto allow for color
development. Mayer’s hematoxylin was used as a coun-
terstain.
RESULTS
Kinetics of IL-la, lL-1, and TNFa
Gene Transcription
In order to determine optimal times to examine the
effects of POE2 on mRNA synthesis, we initially estab-
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Fig. 1. Kinetics of mRNA accumulation in LPS-stimulated (1
pg/mI) CFA macrophages for murine IL-i a, lL-l , and TNFa as
assessed by Northern blot analysis.
TABLE 1. Dose-Dependent Suppression of Cell-Associated
Monokine Bioactlvitles
Suppression of cell-associated bioactivity (%)


















Macrophages were challenged with 1.0 p.g/mi LPS in the presence or
absence of graded concentrations of POE2. After 4 h (time of maximal
cell-associated TNF activity) or 6 h (time of maximal cell-associated
IL-I activity), the monolayers were washed thrice, scraped from their
dishes, and assayed after freeze thawing in 1 ml of culture medium.
Values are mean ± SEM of three determinations.
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Fig. 2. Northern blot analysis of mRNA accumulation for actin, IL-la, IL-i 3, and TNFa
in CFA macrophages treated with: A) control media; B) 1 g/ml LPS + PGE2 lO7M;
or C) 1 pg/mI LPS. Macrophage TNF mRNA was assessed 3 h post-treatment, and IL-l
was assessed 6 h post-treatment.
28s
lEs
lished the kinetics of IL- 1 and TNF mRNA accumulation
following LPS stimulation. As shown in Figure 1, IL-i a
and IL- 113 displayed similar patterns of mRNA accumu-
lation, with peak message expression occurring at 6 h
poststimulation. Message for TNFa achieved maximal
levels sooner, about 3 h poststimulation. These kinetics
paralleled the accumulation of the respective bioactive
materials detected in cell lysates (data not shown).
Regulation of IL-la, IL-i 13, and TNFa by
Prostaglandin E2
We and others have previously reported that POE2 will
dose-dependently inhibit the production of IL- 1 and TNF
activity in stimulated macrophage supernatants [8-11].
Using similar concentrations of POE2, we found no
effect on cell lysate IL- 1 activity, yet PGE2 was effective
in suppressing TNF (Table 1). The results suggest that
POE2 affected IL-l and TNF synthesis and release by
different mechanisms.
To further examine the apparent differential regulation
of TNF and IL-i by POE2, we performed Northern blot
analysis on mRNA isolated at 3 and 6 h, respectively,
from stimulated CFA macrophages that were treated or
untreated with POE2. As shown in Figure 2, the accu-
mulation of actin mRNA was unaffected by LPS or
PGE2, suggesting that these treatments did not non-
specifically affect global mRNA production. Prostaglan-
din E2 at i06 M had no effect on the accumulation of
LPS-induced mRNA for IL-la or 13. In contrast, the
maximal accumulation of TNF mRNA at 3 h was
markedly suppressed by POE2 (greater than 50% as
assessed by laser densitometry), as compared to the
LPS-stimulated control.
As shown in Figure 3, immunohistochemical localiza-
tion of IL-i and TNF confirmed the bioassay experi-
ments. Cellular expression of TNFa, IL-ia, and 13 was
clearly induced by LPS. Interestingly, POE2 had no
effect on cell-associated IL-ia or IL-113 expression.
Conversely, TNF expression was significantly sup-
pressed by 1 M POE2. The staining patterns for IL- 1a
and -13 are suggestive of a diffuse cytoplasmic localiza-
tion of these proteins, whereas the staining for TNFa
appears to be more localized within the cytoplasm (see
arrows, Figure 3f). These distinct staining patterns may
reflect differences in the packaging and cellular process-
ing of these monokines.
I
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Fig. 3. Effect of POE2 on cell-associated monoklne expression monokine expression by Immunolocallzation. a: Anti-IL-ia,
detected Immunohlstochemically. Cells were treated for 6 h (POE2 + LPS). b: Anti-IL-la, (LPS). C: Anti-IL-i (I, (POE2 + LPS).
wIth 1 pglml LPS in the presence or absence of POE2 d: AntI-IL-la, (LPS). e: AntI-TNFa, (PGE2 + LPS). f: AntI-TNFa,
(1 x 1O’M). The monolayers were then fixed and stained for (LPS).
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DISCUSSION
We and others have reported suppression of macro-
phage IL-i and TNF release by POE2 [8-11]. In the
present study, we examined the effect of POE2 on the
production of monokine mRNA and the accumulation of
monokine activity in cell lysates. Northern blot analysis
demonstrated no effect of PGE2 on IL- 1a or -13 mRNA
accumulation, yet TNF mRNA was markedly reduced.
These data suggest that POE2 affected TNF production at
the level of transcription, whereas any affect on IL-i
activity would seem to be post-transcriptional. We have
recently further substantiated (data not shown) this no-
tion by nuclear transcription analyses, showing no effect
of POE2 on genomic IL-la mRNA, yet significant
reductions in genomic mRNA for TNF [22]. These
results do not preclude the possibility of post-tran-
scriptional effects of POE2 on TNF synthesis.
Determination of monokine activities in cell lysates
revealed that both IL-l and TNF activities were detect-
able. Prostaglandin E2 had different effects on these
activities, causing nearly complete suppression of TNF
but not IL- 1 activity. Other investigators have reported
both cytosolic and membrane-associated IL-i activity in
activated macrophage populations [23-27]. Preliminary
studies in our laboratory in which stimulated cells have
been separated into membrane and cytosolic components
suggest that the bulk of cell-associated IL-i bioactivity is
cytosolic, with a much smaller membrane component.
This membrane component, although minimal, may
represent an important functional component. As yet we
have not specifically determined the effect of PGE2 on
membrane associated IL-i activity.
Our immunohistochemical studies lend additional sup-
port to the bioassay data. These studies dramatically
demonstrated that POE2 caused a suppression of TNF but
not IL-la or -13 expression in macrophages. The patterns
of staining suggested that TNF and IL-i are distributed
differently within cells, such that TNF is localized and
IL-i is dispersed in cytoplasm. The diffuse nature of
IL-i staining agrees with the ultrastructural studies of
Singer et al. indicating that IL-l is located in cytoplasmic
ground substance of human monocytes [281.
Interleukin- 1 and tumor necrosis factor share a number
of biological activities. Though similar, these cytokines
act via discrete receptors on target cells, and share no
apparent structural homology. The results of this study
imply that the regulation of these two cytokmnes by a
potential endogenous autokine, prostaglandin E2, is quite
distinct. POE2 exerts a profound inhibition on TNF at the
transcriptional and possibly post-transcriptional level. In
contrast, the previously reported POE2 mediated sup-
pression of IL-i activity in macrophage cultures appears
to be a post-translational event. The differential regula-
tion of these cytokines may have implications as to the
roles of these mediators in health and disease.
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